Page 3 - துறை ஆஃப் பாதுகாப்பு ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana
【新聞看點】李克強只兩條路？俄不抗美北京慌了
ntdtv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ntdtv.com Daily Mail and Mail on Sunday newspapers.
中国疫苗最新权威数据来了！
yicai.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yicai.com Daily Mail and Mail on Sunday newspapers.
国药灭活疫苗Ⅲ期临床数据发布：两针接种14天后保护力超七成_广州日报大洋网
dayoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dayoo.com Daily Mail and Mail on Sunday newspapers.
After 2-DG drug, DRDO develops Covid antibody detection kit
DRDO said three batches of the product were validated for the last one year. The antibody detection kit was approved by the Indian Council of Medical Research (ICMR) in April 2021.
Share Via Email
| A+A A-
The kit is believed to be very useful for understanding COVID-19 epidemiology and assessing an individual s previous SARS-CoV-2 exposure. (Photo | @DRDO India) By Express News Service
NEW DELHI: The Defence Research and Development Organisation (DRDO) has developed an antibody test kit for the early screening of COVID.
DIPCOVAN, the DIPAS-VDx COVID 19 IgG Antibody Microwell ELISA for sero-surveillance has been developed by the Defence Institute of Physiology and Allied Sciences (DIPAS) in association with Delhi-based firm Vanguard Diagnostics Pvt Ltd.
Industry > Industry monitor > Healthcare
13 May 2021
The Drugs Controller General of India (DGCI) on Saturday granted approval for the anti-Covid-19 drug, 2-deoxy-D-glucose (2-DG), developed by a laboratory of the Defence Research and Development Organisation (DRDO) for the treatment of moderate to severe coronavirus patients.
Sateesh Reddy, secretary, Department of Defence Research and Development and chairman, DRDO, said the new drug will be released either on Tuesday or Wednesday. Reddy said the drug can deal with any virus strain. This assumes importance in view of the new Covid strains emerged during the second wave of the pandemic.
The drug molecule, developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence. Clinical trials have shown that higher proportion of Covid patients treated with 2-DG has be